All In Biotech

Investigational drug · Phase 3

Arlocabtagene Autoleucel

Also called: BMS-986393, GPRC5D CAR T cells

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM).

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3

Any phase or sponsor naming "Arlocabtagene Autoleucel"

First trial start

2024

Mar 21, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Arlocabtagene Autoleucel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Multiple Myeloma
  • Relapsed or Refractory Multiple Myeloma (RRMM)

Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Arlocabtagene Autoleucel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Multiple Myeloma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.